Elicio Therapeutics prices $15M registered direct offering

Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.

The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.

The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and platform, working capital, and general corporate purposes.

Titan Partners, a division of American Capital Partners, is serving as lead placement agent. B. Riley Securities, Inc. is acting as co-placement agent.

The offering is being made pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission on March 16, 2026.

ELI-002 7P was previously evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with KRAS-mutation-positive pancreatic cancer who completed standard therapy but remained at high risk of relapse. Based on topline results and post-hoc analyses, Elicio said it has refined its Phase 3 development strategy to focus on patients with lower residual disease burden and extended treatment duration.

You May Also Be Interested In

• Daré Bioscience prices $6M direct offering at $1.37 per share
• Zentalis Pharmaceuticals prices $80.5M public stock offering
• Silence Therapeutics closes $201M public offering of ADSs